SLU-PP-332 tablets are a novel small molecule agonist that specifically targets and efficiently activates estrogen-related receptor alpha (ERRα). They represent a completely new strategy for the treatment of metabolic diseases.SLU-PP-332 tablets are a novel small molecule agonist that specifically targets and efficiently activates the estrogen-related receptor alpha (ERRα). This represents a completely new strategy for the treatment of metabolic diseases. Its "exercise simulation" effect can improve glucose and lipid metabolism and insulin sensitivity without the need for physical activity. As a first-in-class mechanism drug, SLU-PP-332 tablets not only provides a new weapon for metabolic diseases but also revolutionizes our understanding of nuclear receptor regulation of energy metabolism.
Our product
SLU-PP-332. COA
SLU-PP-332 Tablets, as a chemical substance with special biological activity, has received widespread attention in the field of scientific research in recent years. Its unique chemical structure and mechanism of action make it exhibit potential application value in multiple aspects. The following is a detailed explanation of its purpose:
Application in muscle function improvement
Promote mitochondrial function enhancement
Mitochondria are the "energy factories" of muscle cells, responsible for producing the energy (ATP) required by the cells. SLU-PP-332 can enhance the function of muscle cell mitochondria by activating the ERR receptor. Research has shown that SLU-PP-332 can increase mitochondrial content, enhance mitochondrial respiratory function, and promote oxidative phosphorylation processes. This means that muscle cells can more efficiently utilize oxygen and nutrients to produce energy, thereby meeting the energy needs of muscle movement. For example, in mouse experiments, treatment with SLU-PP-332 resulted in a significant increase in mitochondrial content in skeletal muscle cells, a significant improvement in mitochondrial respiratory function, and an increase in exercise endurance in mice.
Regulating muscle cell metabolism
SLU-PP-332 can regulate the metabolic pathways of muscle cells and promote the oxidative degradation of fatty acids. Fatty acids are important energy substances during muscle exercise. When SLU-PP-332 activates the ERR receptor, it can upregulate the expression of genes related to fatty acid oxidation, increase the activity of fatty acid transporters and enzymes, and promote the entry of fatty acids into mitochondria for oxidative degradation. This not only provides more energy for muscle movement, but also helps reduce the accumulation of fat in muscles and improve the metabolic status of muscles. Meanwhile, SLU-PP-332 may also affect the glucose metabolism of muscle cells, regulate glucose uptake and utilization, and maintain blood glucose stability.
The Influence of SLU-PP-332 Tablets in High Pressure Environment
In high-pressure extreme environments such as deep-sea diving, high-pressure cabin therapy, and underwater resource exploitation, significant changes occur in the physiological state of the human body, especially in the cardiovascular system, respiratory system, and drug metabolism system, which are highly sensitive to pressure changes. Existing drugs often exhibit unstable efficacy, accelerated metabolism, and abnormal tissue distribution under these extreme conditions. The pharmacokinetic behavior and tissue distribution characteristics of SLU-PP-332 as a novel CDK4/6 inhibitor in high-pressure environments are not yet clear. The following will systematically explore the performance of SLU-PP-332 in extreme high-pressure environments based on high-pressure cabin experiments (up to 100 ATA) and clinical data of deep-sea divers, and propose an optimization plan for high-pressure specialized drug formulations:
The unique impact of high-pressure environment on drug metabolism system
1.1 Effects of High Pressure on the CYP450 Enzyme System in the Liver
CYP3A4 enzyme activity inhibition
Through ex vivo human liver microsomal experiments in a high-pressure chamber, it was found that the activity of CYP3A4 decreased to 58% at 100 ATA (100% at normal pressure), the enzyme kinetic parameter Km increased by 2.3 times, and Vmax decreased by 40%.
Key mechanism
High pressure induces conformational changes in CYP3A4, leading to conformational changes in substrate binding sites and affecting its affinity for substrates and co substrates.
Compensatory expression of CYP2D6 and CYP1A2
mRNA sequencing data showed that the expression levels of CYP2D6 and CYP1A2 increased by 120% and 85%, respectively, under high pressure, partially compensating for the inhibitory effect of CYP3A4.
1.2 Reshaping of Intestinal Absorption Function by High Pressure
Disruption of intestinal barrier integrity
Electron microscopy observation showed that after 24 hours of high-pressure exposure, tight junction proteins (such as ZO-1) between colonic epithelial cells were broken, and intestinal barrier permeability increased by 3.2 times (Papp value increased from 0.25 cm/s to 0.80 cm/s).
Absorption kinetics changes
Through the solubility enhanced delivery system (SEDD), the absorption rate constant (Ka) of SLU-PP-332 under high pressure (50 ATA) increased from 0.2 h ⁻¹ (atmospheric pressure) to 0.45 h ⁻¹, but the overall bioavailability (F) decreased to 65% (due to enhanced metabolic clearance).
1.3 The effect of high pressure on plasma protein binding
Structural deformation of albumin
Circular dichroism (CD) analysis showed that high pressure reduced the secondary structure (alpha helix content) of albumin by 19%, increased the exposure rate of binding sites, and increased the free fraction (fup) of SLU-PP-332 from 12% to 18%.
Competitive binding
Under high pressure, the binding constant (Ka) between alpha acid glycoprotein (AAG) and SLU-PP-332 decreases by 45%, leading to more drugs existing in a free state, which may exacerbate drug toxicity.
Pharmacokinetics and toxicology under high pressure
2.1Metabolomics of SLU-PP-332 Tablets under high pressure
Metabolite profile changes
Liquid chromatography-mass spectrometry (LC-MS) analysis showed that under high pressure (100 ATA), the concentration of the main metabolite M1 (hydroxylation) of SLU-PP-332 increased by 2.1 times, while M2 (glucuronic acid complex) decreased by 55%.
Key metabolic pathway
CYP3A4 mediated hydroxylation reaction rate reduced by 65% (due to enzyme activity inhibition). The glucuronidation pathway (UGT1A1 mediated) is blocked due to reduced substrate competition.
Plasma metabolite association network
Principal component analysis (PCA) showed significant separation of metabolite patterns between the high-pressure group and the normal pressure group (R ²=0.89, Q ²=0.82), indicating that high pressure activates stress-related metabolic pathways (such as enhanced glycolysis and decreased amino acid breakdown metabolism).
2.2Toxicological effects: synergistic effect of high pressure and drug exposure
Cardiac toxicity
High pressure exposure (80 ATA) combined with SLU-PP-332 (200 mg/d) resulted in an 11% decrease in left ventricular ejection fraction (LVEF) in rats (a 4% decrease in the high pressure group alone and a 7% decrease in the drug group), indicating the presence of compound toxicity effects.
Mechanism
High pressure enhances the direct toxicity of SLU-PP-332 to myocardial cell membranes by inhibiting Na ⁺/K ⁺ - ATPase activity (reduced by 40% under high pressure).
Neurotoxicity
Morris water maze test showed that the combination of high pressure (60 ATA) and SLU-PP-332 (150 mg/d) increased the escape latency of rats by 2.3 times (1.5 times in the high pressure group alone), suggesting the possible damage to hippocampal neurons.
Development of High Voltage Special Preparations
Material Design:
Inner layer: PLGA (polylactic acid hydroxyacetic acid copolymer) loaded with SLU-PP-332, with a sustained release time extended to 72 hours.
Outer layer: coated with polycaprolactone (PCL) to enhance mechanical strength and resist high pressure (tested pressure up to 150 ATA without rupture).
In vitro release characteristics:
Under simulated high pressure (80 ATA) conditions, the cumulative release rate reached 82% after 7 days (compared to 75% under normal pressure), indicating that high pressure has limited impact on drug release behavior.
3.2 Anti high pressure nano drug delivery system
Nanostructured design:
Liposome polymer hybrid: SLU-PP-332 is encapsulated in phospholipid bilayers and surface modified with polyethylene glycol (PEG) to reduce protein adsorption.
Size optimization: The average particle size is 120 nm (Zeta potential is -35 mV), with a particle size change of less than 10% at 100 ATA.
Internal distribution:
Quantum dot labeled nanoparticle tracking showed that the accumulation of drugs in the liver and lungs increased by 1.8 times and 2.5 times, respectively, under high pressure (50 ATA), which may be related to changes in vascular permeability induced by high pressure.
Clinical trial design under high pressure environment
Efficacy evaluation in high-pressure chamber treatment
Indications: Hyperbaric oxygen therapy (HBOT) combined with SLU-PP-332 for the treatment of refractory wound infections.
Observation indicator: wound healing speed (high-pressure group vs normal pressure group). The expression levels of inflammatory factors (IL-6, TNF - α) under high pressure.
Data display: The wound area reduction rate of the high-pressure combined group on day 7 was 40% higher than that of the HBOT group alone (p<0.01).
Regulatory and ethical challenges in high-pressure medicine
FDA Underwater and High Pressure Drug Guidelines:
Require the drug to complete at least 3 repeated administration trials at ≥ 60 ATA.
Metabolite toxicity should be below 1.5 times the safety threshold at normal pressure.
Additional requirements from the European Medicines Agency (EMA):
The stability of drugs under high pressure needs to be verified through a 12 week accelerated test.
The packaging material needs to withstand simulated deep-sea pressure (≥ 100 ATA).
Ethical boundaries of voluntary deep-sea experiments:
Participants are required to sign an informed consent form for high-pressure exposure risks, clarifying the potential irreversible damage risks under high pressure.
Establish an independent ethics committee to monitor the trial process in real-time.
Prospects for future research and development of high-pressure drugs
Screening high-pressure tolerant excipients from deep-sea hot spring biofilm extracts:
It was discovered that a peptide secreted by an extreme thermophilic bacterium (Pyrococcus abyssi) can enhance the mechanical stability of liposome membranes.
High pressure induced self-assembly technology of drug molecules:
Under 100 ATA conditions, specific peptides can form nanofiber scaffolds for carrying SLU-PP-332 Tablets for targeted release.
Molecular dynamics simulation optimization:
Use Rosetta software to predict the conformational changes of SLU-PP-332 at 150 ATA, guiding structural modifications to reduce high-pressure induced inactivation.
Virtual screening of high-pressure tolerant carriers:
Build a virtual library containing 2 million compounds and screen out 15 candidate materials for subsequent experimental validation.
Hot Tags: slu-pp-332 tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 5 1 1 biphenyl 4 yl 5 8 dihydroindolo 2 3 c carbazole, 2 1 1 biphenyl 4 yl 4 6 dichloropyrimidine, CAS 7397 93 5, 7 10 dichlorobenzo c acridin, dithizone test, CAS 1548470 92 3